Combinatorial Genetic Engineering Approach for Targeted Immune Protection of Stem Cell-Derived Beta Cells by CAR Tregs For Treatment of Type 1 Diabetes
Immune suppression via engineered hPSC stem cells Demonstrated for T1D Can be used for immune suppression of any stem-cell-derived tissues
Polycaprolactone Nanocapsules as a Tailorable Drug Delivery Platform to Specifically Targeted Human Pancreatic Beta Cells
Nanocapsules can be fine-tuned for drug release time scales of hours to months Novel formulation that allows facile and interchangeable attachment of surface molecules, including antibodies and peptides Ability to encapsulate both hydrophobic and hydrophilic drugs for controlled release Provides a novel mechanism to target the islet beta cell for delivery of therapeutics
Novel Synthetic ERR Agonists II
High-affinity ERR Agonists Effective in models of heart failure, metabolic disease, and cognitive dysfunction